Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för GSK591. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

8 träffar

Bibliografisk träff 2024-01-03

PRMT5 inhibition shows in vitro efficacy against H3K27M-altered diffuse midline glioma, but does not extend survival in vivo.

Brown EJ, Balaguer-Lluna L, Cribbs AP, Philpott M, Campo L, Browne M, Wong JF, Oppermann U, Carcaboso ÁM, Bullock AN, Farnie G.

Sci Rep · research-article; journal article · DOI 10.1038/s41598-023-48652-x

Bibliografisk träff 2024-01-01

CircMMP2(6,7) Cooperates with β-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis.

Xu Y, Li X, Zhang S, Tang M, Yu R, Liao X, Li Z, Li M, Chen S, Qian W, Song L, Ke Z, Li J.

Cancer Res · research support, non-u.s. gov't; journal article · DOI 10.1158/0008-5472.can-23-1899

Bibliografisk träff 2021-02-12

PRMT5 inhibition disrupts splicing and stemness in glioblastoma.

Sachamitr P, Ho JC, Ciamponi FE, Ba-Alawi W, Coutinho FJ, Guilhamon P, Kushida MM, Cavalli FMG, Lee L, Rastegar N, Vu V, Sánchez-Osuna M, Coulombe-Huntington J, Kanshin E, Whetstone H, Durand M, Thibault P, Hart K, Mangos M, Veyhl J, Chen W, Tran N, Duong BC, Aman AM, Che X, Lan X, Whitley O, Zaslaver O, Barsyte-Lovejoy D, Richards LM, Restall I, Caudy A, Röst HL, Bonday ZQ, Bernstein M, Das S, Cusimano MD, Spears J, Bader GD, Pugh TJ, Tyers M, Lupien M, Haibe-Kains B, Artee Luchman H, Weiss S, Massirer KB, Prinos P, Arrowsmith CH, Dirks PB.

Nat Commun · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/s41467-021-21204-5

Bibliografisk träff 2021-01-27

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression.

Yang L, Ma DW, Cao YP, Li DZ, Zhou X, Feng JF, Bao J.

Theranostics · research support, non-u.s. gov't; research-article; journal article · DOI 10.7150/thno.53023

Bibliografisk träff 2021-01-20

PRMT5 regulates colorectal cancer cell growth and EMT via EGFR/Akt/GSK3β signaling cascades.

Yan Y, Zhao P, Wang Z, Liu Z, Wang Z, Zhang J, Ding Y, Hua X, Yu L.

Aging (Albany NY) · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/aging.202407

Bibliografisk träff 2021-01-01

PRMT5 Promotes EMT Through Regulating Akt Activity in Human Lung Cancer.

Huang J, Zheng Y, Zheng X, Qian B, Yin Q, Lu J, Lei H.

Cell Transplant · research support, non-u.s. gov't; research-article; journal article · DOI 10.1177/09636897211001772

Bibliografisk träff 2019-10-30

PRMT5 Promotes Human Lung Cancer Cell Apoptosis via Akt/Gsk3β Signaling Induced by Resveratrol.

Li Y, Yang Y, Liu X, Long Y, Zheng Y.

Cell Transplant · research support, non-u.s. gov't; research-article; journal article · DOI 10.1177/0963689719885083

Bibliografisk träff 2018-11-20

Targeting PRMT5/Akt signalling axis prevents human lung cancer cell growth.

Zhang S, Ma Y, Hu X, Zheng Y, Chen X.

J Cell Mol Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/jcmm.14036